PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

HIV and cancer : What's new in 2017?

Abstract Since the era of combined antiretroviral therapy, life expectancy of people living with HIV has been improved and is associated with a change in causes of death. Cancer, both AIDS-defining or non-AIDS-defining cancers, has become the leading cause of death in people living with HIV associated with an increase in the incidence of some cancers compared to the general population. Epidemiology and the identification of risk factors is a crucial issue, particularly to determine the most appropriate prevention and screening strategies in this population. In the absence of dedicated clinical trials, the cancer management in these patients is based on general recommendations, with specific attention to comorbidities and drug interactions. In addition, the development of new innovative therapies such as immunotherapy with inhibitory antibodies of immune checkpoints receptor represents a hope for the patient care, both infected or not with HIV. In this context, the establishment of the national network CancerVIH makes sense, allowing the establishment of multi-disciplinary consultation meetings involving all the practitioners involved in the care of these patients with cancer, as well as the constitution of a national cohort and the promotion of dedicated trials, to improve and optimize the management for these patients.
PMID
Related Publications

Changes in mortality rates and causes of death in a population-based cohort of persons living with and without HIV from 1996 to 2012.

Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.

HIV-related malignancies: state of art.

Cancer in the HIV-Infected Host: Epidemiology and Pathogenesis in the Antiretroviral Era.

Lung cancer in HIV-infected patients.

Authors

Mayor MeshTerms
Keywords

Cancer

Dépistage

HIV

Immune therapy

Immunothérapie

Screening

VIH

Journal Title bulletin du cancer
Publication Year Start




PMID- 29548534
OWN - NLM
STAT- MEDLINE
DCOM- 20180329
LR  - 20180329
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 105
IP  - 3
DP  - 2018 Mar
TI  - [HIV and cancer : What's new in 2017?]
PG  - 256-262
LID - S0007-4551(18)30055-9 [pii]
LID - 10.1016/j.bulcan.2018.02.002 [doi]
AB  - Since the era of combined antiretroviral therapy, life expectancy of people
      living with HIV has been improved and is associated with a change in causes of
      death. Cancer, both AIDS-defining or non-AIDS-defining cancers, has become the
      leading cause of death in people living with HIV associated with an increase in
      the incidence of some cancers compared to the general population. Epidemiology
      and the identification of risk factors is a crucial issue, particularly to
      determine the most appropriate prevention and screening strategies in this
      population. In the absence of dedicated clinical trials, the cancer management in
      these patients is based on general recommendations, with specific attention to
      comorbidities and drug interactions. In addition, the development of new
      innovative therapies such as immunotherapy with inhibitory antibodies of immune
      checkpoints receptor represents a hope for the patient care, both infected or not
      with HIV. In this context, the establishment of the national network CancerVIH
      makes sense, allowing the establishment of multi-disciplinary consultation
      meetings involving all the practitioners involved in the care of these patients
      with cancer, as well as the constitution of a national cohort and the promotion
      of dedicated trials, to improve and optimize the management for these patients.
CI  - Copyright (c) 2018 Societe Francaise du Cancer. Published by Elsevier Masson SAS.
      All rights reserved.
FAU - Gobert, Aurelien
AU  - Gobert A
AD  - Assistance publique-Hopitaux de Paris, hopital Pitie-Salpetriere, service
      d'oncologie medicale, 47, boulevard de l'Hopital, 75013 Paris, France. Electronic
      address: [email protected]
FAU - Veyri, Marianne
AU  - Veyri M
AD  - Assistance publique-Hopitaux de Paris, hopital Pitie-Salpetriere, service
      d'oncologie medicale, 47, boulevard de l'Hopital, 75013 Paris, France.
FAU - Poizot-Martin, Isabelle
AU  - Poizot-Martin I
AD  - Assistance publique-Hopitaux de Marseille, CHU Sainte-Marguerite, service
      d'immuno-hematologie clinique, 20, avenue Viton, 13274 Marseille, France.
FAU - Lavole, Armelle
AU  - Lavole A
AD  - Hopital Tenon, service de pneumologie, 4, rue de la Chine, 75020 Paris, France.
FAU - Solas, Caroline
AU  - Solas C
AD  - Assistance publique-Hopitaux de Marseille, hopital de la Timone, service de
      pharmacocinetique toxicocinetique, 264, rue Saint-Pierre, 13005 Marseille,
      France.
FAU - Paliche, Romain
AU  - Paliche R
AD  - Assistance publique-Hopitaux de Paris, hopital Pitie-Salpetriere, service des
      maladies infectieuses et tropicales, 47, boulevard de l'Hopital, 75013 Paris,
      France.
FAU - Katlama, Christine
AU  - Katlama C
AD  - Assistance publique-Hopitaux de Paris, hopital Pitie-Salpetriere, service des
      maladies infectieuses et tropicales, 47, boulevard de l'Hopital, 75013 Paris,
      France.
FAU - Costagliola, Dominique
AU  - Costagliola D
AD  - Institut Pierre-Louis d'epidemiologie et de sante publique (IPLESP UMRS 1136),
      Sorbonne-universites, UPMC universite Paris-06, Inserm, 75013 Paris, France.
FAU - Spano, Jean-Philippe
AU  - Spano JP
AD  - Assistance publique-Hopitaux de Paris, hopital Pitie-Salpetriere, service
      d'oncologie medicale, 47, boulevard de l'Hopital, 75013 Paris, France; Institut
      Pierre-Louis d'epidemiologie et de sante publique (IPLESP UMRS 1136),
      Sorbonne-universites, UPMC universite Paris-06, Inserm, 75013 Paris, France.
LA  - fre
PT  - Journal Article
PT  - Review
TT  - Cancer et VIH : actualites 2017.
DEP - 20180313
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Anti-HIV Agents)
SB  - IM
MH  - Anti-HIV Agents/therapeutic use
MH  - Cancer Care Facilities/organization & administration
MH  - Cause of Death
MH  - Chronic Disease
MH  - Comorbidity
MH  - Drug Interactions
MH  - Female
MH  - HIV Infections/complications/mortality/*therapy
MH  - Humans
MH  - Immunotherapy/methods
MH  - Life Expectancy
MH  - Male
MH  - Middle Aged
MH  - Neoplasms/complications/*drug therapy
MH  - Patient Care Team/organization & administration
MH  - Risk Factors
OTO - NOTNLM
OT  - Cancer
OT  - Depistage
OT  - HIV
OT  - Immune therapy
OT  - Immunotherapie
OT  - Screening
OT  - VIH
EDAT- 2018/03/20 06:00
MHDA- 2018/03/30 06:00
CRDT- 2018/03/18 06:00
PHST- 2017/11/14 00:00 [received]
PHST- 2018/02/01 00:00 [revised]
PHST- 2018/02/02 00:00 [accepted]
PHST- 2018/03/20 06:00 [pubmed]
PHST- 2018/03/30 06:00 [medline]
PHST- 2018/03/18 06:00 [entrez]
AID - S0007-4551(18)30055-9 [pii]
AID - 10.1016/j.bulcan.2018.02.002 [doi]
PST - ppublish
SO  - Bull Cancer. 2018 Mar;105(3):256-262. doi: 10.1016/j.bulcan.2018.02.002. Epub
      2018 Mar 13.